<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266537</url>
  </required_header>
  <id_info>
    <org_study_id>527.70</org_study_id>
    <nct_id>NCT02266537</nct_id>
  </id_info>
  <brief_title>Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers</brief_title>
  <official_title>A Parallel Group Study With Three Different α-antagonists and Placebo Once Daily Over Three Weeks to Assess Their Influence on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The study was aimed to evaluate the pharmacological effect of different α-antagonists on
      phenylephrine induced pupil size in healthy male volunteers as pharmacological basis for
      Intraoperative floppy iris syndrome (IFIS)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of changes from baseline in the mean pupil diameters</measure>
    <time_frame>Baseline, 60 and 80 min after administration of phenylephrine (PE)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean diameter of both pupils</measure>
    <time_frame>Baseline, 60 and 80 min after administration of phenylephrine (PE)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean diameter of both pupils</measure>
    <time_frame>one week after cessation of drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of the analyte in plasma</measure>
    <time_frame>Up to 29 days after first administration of α-antagonists</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs</measure>
    <time_frame>Up to 8 days after last pupillometry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal changes in clinical laboratory parameters</measure>
    <time_frame>Up to 8 days after last pupillometry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Up to 8 days after last pupillometry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessement of global tolerability by investigator on a 4 point scale</measure>
    <time_frame>8 days after last pupillometry</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tamsulosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alfuzosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxazosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <arm_group_label>Tamsulosin</arm_group_label>
    <other_name>Alna®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfuzosin</intervention_name>
    <arm_group_label>Alfuzosin</arm_group_label>
    <other_name>Uroxatral® uno</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin</intervention_name>
    <arm_group_label>Doxazosin</arm_group_label>
    <other_name>Cardular PP Uro®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male

          -  Age ≥ 21 and ≤ 55 years

          -  Body Mass Index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2

          -  Signed and dated written informed consent in accordance with Good Clinical Practice
             (GCP) and local legislation

        Exclusion Criteria:

          -  Any finding of the medical examination (including blood pressure, pulse rate and
             Electrocardiogram (ECG)) deviating from normal and of clinical relevance

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (&gt; 24:00 hours) within at least one month or
             less than ten half-lives of the respective drug before enrolment in the study or
             during the study

          -  Use of any drugs which might influence the results of the trial up to seven days prior
             to enrolment in the study or during the study

          -  Participation in another trial with an investigational drug (≤ two months prior to
             administration or during the trial)

          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

          -  Inability to refrain from smoking on in-house trial days

          -  Alcohol abuse (&gt; 60 g/day)

          -  Drug abuse

          -  Blood donation (≥ 100 mL within four weeks prior to administration or during the
             trial)

          -  Any laboratory value outside the clinically accepted reference range

          -  Excessive physical activities within the last week before the trial or during the
             trial

        The following exclusion criteria are of special interest for this study:

          -  Hypersensitivity to any alpha agonist, or to phenylephrine

          -  Supine blood pressure at screening of systolic &lt; 110 mmHg and diastolic &lt; 60 mmHg

          -  Ophthalmological criteria:

               -  Corrected visual acuity &lt; 0.5

               -  Refractive Error with a spherical equivalent &gt; +6 or smaller - 6 D

               -  Elevated intraocular pressure (higher than 22 mmHg)

               -  Relevant anisocoria or pupil deformation

               -  History of eye surgery apart from laser trabeculoplasty less than three months
                  previously or extraocular surgery such as strabismus surgery

               -  Topical ocular medication influencing IOP (intraocular pressure) or pupil size
                  within 3 months prior to study-start
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>October 16, 2014</last_update_submitted>
  <last_update_submitted_qc>October 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mydriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Doxazosin</mesh_term>
    <mesh_term>Alfuzosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

